Abstract Use of robust, quantitative tools to measure patient perspectives within product development and regulatory review processes offers the opportunity for medical device researchers, regulators, and other stakeholders to evaluate what matters most to patients and support the development of products that can best meet patient needs. The medical device innovation consortium (MDIC) undertook a series of projects, including multiple case studies and expert consultations, to identify approaches for utilizing patient preference information (PPI) to inform clinical trial design in the US regulatory context. Based on these activities, this paper offers a cogent review of considerations and opportunities for researchers seeking to...
BACKGROUND: Clinical trial design requires value judgements and understanding patient preferences ma...
The focus of this thesis is a new quantitative approach to consider patient preferences on benefits ...
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objective: Patients have unique insights and are (in-)directly affected by each decision taken throu...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical ind...
Currently, patient preference studies are not required to be included in marketing authorization app...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical in...
Currently, patient preference studies are not required to be included in marketing authorization app...
Patient preferences are critical for the successful development, regulation, and reimbursement of me...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical ind...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should ...
Introduction: There is a growing trend of using patient preference studies to help incorporate the p...
BACKGROUND: Clinical trial design requires value judgements and understanding patient preferences ma...
The focus of this thesis is a new quantitative approach to consider patient preferences on benefits ...
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objective: Patients have unique insights and are (in-)directly affected by each decision taken throu...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical ind...
Currently, patient preference studies are not required to be included in marketing authorization app...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical in...
Currently, patient preference studies are not required to be included in marketing authorization app...
Patient preferences are critical for the successful development, regulation, and reimbursement of me...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical ind...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should ...
Introduction: There is a growing trend of using patient preference studies to help incorporate the p...
BACKGROUND: Clinical trial design requires value judgements and understanding patient preferences ma...
The focus of this thesis is a new quantitative approach to consider patient preferences on benefits ...
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...